Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 245-253

  Liu, Yang ^a   Butterfield, Lisa H ^c   Fu, Xiaohui ^b   Song, Zhenshun ^a   Zhang, Xiaoping ^a   Lu, Chongde ^b   Ding, Guanghui ^a   Wu, Mengchao ^b  

^a TONGJI UNIVERSITY   (China)

^b Eastern Institute of Hepatobiliary Surgery   (China)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

fetoprotein; AFP; Cytokine; Dendritic cell; T cells

Indexed keywords

ALPHA FETOPROTEIN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCYLVALYLALANYLLEUCYLGLUTAMINYLTHREONYLMETHIONYLLYSYLGLUTAMINE; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 2; LENTIVIRUS VECTOR; METHIONYLLYSYLTRYPTOPHYLVALYLGLUTAMYLSERYLISOLEUCYLPHENYLALANYLLEUCINE; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN HEPG2; CYTOKINE PRODUCTION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION; TH1 CELL; XENOGRAFT;

ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EPITOPES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEK293 CELLS; HEP G2 CELLS; HUMANS; LENTIVIRUS; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, NUDE; PEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79955988877     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1004     Document Type: Article

References (41)

1. Levin B and Amos C: Therapy of unresectable hepatocellular carcinoma [editorial; comment] [published erratum appears in N Engl J Med 333: 675, 1995]. N Engl J Med 332: 1294-1296, 1995.
2. Fisher RA, Maroney TP, Fulcher AS, et al: Hepatocellular carcinoma: strategy for optimizing surgical resection, transplantation and palliation. Clin Transplant 16 (Suppl 7): 52-58, 2002. (Pubitemid 41185586)
3. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411: 380-384, 2001.
4. Abelev GI and Eraiser TL: Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol 9: 95-107, 1999. (Pubitemid 29265525)
5. Isaacs H Jr: Fetal and neonatal hepatic tumors. J Pediatr Surg 42: 1797-1803, 2007.
6. Mizejewski GJ: Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther 2: 709-735, 2002.
7. Kubota M, Yagi M, Kanada S, et al: Effect of postoperative chemotherapy on the serum alpha-fetoprotein level in hepatoblastoma. J Pediatr Surg 39: 1775-1778, 2004. (Pubitemid 40017713)
8. Nakagawara A, Ikeda K, Tsuneyoshi M, et al: Hepatoblastoma producing both alpha-fetoprotein and human chorionic gonadotropin. Clinicopathologic analysis of four cases and a review of the literature. Cancer 56: 1636-1642, 1985.
9. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
10. Fong L, Brockstedt D, Benike C, Wu L and Engleman EG: Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166: 4254-4259, 2001. (Pubitemid 32224961)
11. Ladanyi A, Kiss J, Somlai B, et al: Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56: 1459-1469, 2007. (Pubitemid 47024707)
12. Verra N, de Jong D, Bex A, et al: Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 48: 527-533, 2005. (Pubitemid 41188416)
13. Rasaiyaah J, Noursadeghi M, Kellam P and Chain B: Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line. Immunology 127: 429-441, 2009.
14. Butterfield LH, Meng WS, Koh A, et al: T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166: 5300-5308, 2001. (Pubitemid 32280749)
15. Butterfield LH, Koh A, Meng W, et al: Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59: 3134-3142, 1999. (Pubitemid 29316013)
16. Butterfield LH, Ribas A, Meng WS, et al: T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9: 5902-5908, 2003. (Pubitemid 38018074)
17. Meng WS, Butterfield LH, Ribas A, et al: alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 61: 8782-8786, 2001. (Pubitemid 34013891)
18. Vollmer CM Jr, Eilber FC, Butterfield LH, et al: Alpha-fetoprotein- specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59: 3064-3067, 1999. (Pubitemid 29316002)
19. Butterfield LH, Ribas A, Dissette VB, et al: A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12: 2817-2825, 2006.
20. Butterfield LH, Ribas A, Potter DM and Economou JS: Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother 56: 1931-1943, 2007.
21. Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM and Butterfield LH: Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 177: 712-721, 2006. (Pubitemid 43939186)
22. Gonzalez-Carmona MA, Marten A, Hoffmann P, et al: Patient-derived dendritic cells transduced with an α-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 26: 369-379, 2006. (Pubitemid 43349329)
23. Naldini L: Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 9: 457-463, 1998.
24. Arthur JF, Butterfield LH, Roth MD, et al: A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4: 17-25, 1997.
25. Romani N, Gruner S, Brang D, et al: Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83-93, 1994. (Pubitemid 24181058)
26. Plebanski M, Allsopp CE, Aidoo M, Reyburn H and Hill AV: Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur J Immunol 25: 1783-1787, 1995.
27. Butterfield LH, Jilani SM, Chakraborty NG, et al: Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 161: 5607-5613, 1998. (Pubitemid 28519126)
28. Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR and Ergin MT: Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169: 1961-1976, 1989.
29. Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, et al: Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 27: 191-200, 2004. (Pubitemid 39118083)
30. Zhang Z, Liu Q, Che Y, et al: Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3. Cancer Res 70: 89-98, 2010.
31. Schakel K: Dendritic cells - why can they help and hurt us. Exp Dermatol 18: 264-273, 2009.
32. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Banchereau J, et al: Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA 104: 20884-20889, 2007.
33. Chaput N, Conforti R, Viaud S, Spatz A and Zitvogel L: The Janus face of dendritic cells in cancer. Oncogene 27: 5920-5931, 2008.
34. Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL and Butterfield LH: Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15 Blood 116: 575-583, 2010.
35. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al: alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64: 5934-5937, 2004. (Pubitemid 39129387)
36. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, et al: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196: 619-628, 2002. (Pubitemid 35024440)
37. Meng WS and Butterfield LH: Activation of antigen-presenting cells by DNA delivery vectors. Expert Opin Biol Ther 5: 1019-1028, 2005. (Pubitemid 41170032)
38. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, et al: Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 10: 7260-7269, 2004. (Pubitemid 39487713)
39. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O and Moser M: Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 27: 1229-1235, 1997. (Pubitemid 27197228)
40. Berke G: The CTLs kiss of death. Cell 81: 9-12, 1995.
41. Hayashida M, Kawano H, Nakano T, Shiraki K and Suzuki A: Cell death induction by CTL: perforin/granzyme B system dominantly acts for cell death induction in human hepatocellular carcinoma cells. Proc Soc Exp Biol Med 225: 143-150, 2000.